Influence of preparation method on itraconazole oral solutions using cyclodextrins as complexing agents

Pharmazie

Volumn 62, Issue 7, 2007, Pages 510-514

  Holvoet, C ^a   Vander Heyden, Y ^a   Plaizier Vercammen, J ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 7 BETA CYCLODEXTRIN SULFOBUTYL ETHER; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN DERIVATIVE; ITRACONAZOLE; MALTOSYL BETA CYCLODEXTRIN; PROPYLENE GLYCOL; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DISSOLUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG SYNTHESIS; PH; SOLUBILITY;

ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLODEXTRINS; DRUG COMPOUNDING; EXCIPIENTS; ITRACONAZOLE; PHARMACEUTICAL SOLUTIONS; SOLUBILITY;

EID: 34447543016     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.7.6277     Document Type: Article

References (30)

1. Barone JA, Moskovitz BL, Guarnieri J, Hassel AE, Colaizi JL, Bierman RH, Jessen L (1998) Enhanced bioavailability of itraconazole in hydroxypropyl- β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 42: 1862-1865.
2. Brewster ME, Simpkins JW, Maninder SH, Warren CS, Bodor N (1989) The potential use of cyclodextrins in parenteral formulations. J. Parenter Sci Technol 43: 231-240.
3. Cedilla et al. (1988) Patent Janssen Pharmaceutica, Beerse, Belgium, US Patent 5,707,975.
4. Compas D, Touw DJ, de Goede PNFC (1996) Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography. J Chromatogr B 687: 453-456.
5. DAB, Deutsches Arzneibuch (1999) Kommentar zur Europäischen Pharmacopea, Arzneibuch-Kommentar Wissenschaftliche Erläuterangen zum Arzneibuch, Wissenschaftliche Verlagsgesellschaft, Stuttgart, p. 1335-1339.
6. De Beule K, Van Gestel J (2001) Pharmacology of itraconazole. Drugs 61: 27-37.
7. rd edition supplement, Council of Europe, Strasbourg, France.
8. Higuchi T, Connors KA (1965) Phase-solubility techniques. Adv Anal Chem Instrum 4: 117-212.
9. Holvoet C, Vander Heyden Y, Plaizier-Vercammen J (2005a) Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use. Pharmazie 60: 598-603.
10. Holvoet C, Vander Heyden Y, Plaizier-Vercammen J (2005b) Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use. Drug Dev Ind Pharm 31: 567-575.
11. Hostetler JS, Hanson LH, Stevens DA (1992) Effect of cyclodextrin on pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 2: 477-480.
12. http://www.cydexinc.com (accessed November 2006)
13. Irie T, Uekama K (1997) Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86: 147-162.
14. Jacobson PA, Johnson CE, Walters JR (1995) Stability of itraconazole in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm 52: 189-191.
15. Jaruratanasirikul S, Kleepkaew A (1997) Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 52: 235-237.
16. Loftsson T, Olafsdottir BJ, Frioriksdottir H, Jonsdottir (1993) Cyclodextrins complexation of NSAIDs: physicochemical characteristics. Eur J Pharm Sci 1: 95-101.
17. Loftsson T, Brewster M (1996) Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85: 1017-1025.
18. Loftsson T, Brewster M (1997) Cyclodextrins as pharmaceutical excipients. Pharm Tech Eur 9: 26-34.
19. MacCallum DM, Odds FC (2002) Efficacy of parenteral itraconazole against disseminated Candida albicans infection in two mouse strains. JAC 50: 225-229.
20. Miyake K, Irie T, Arima H, Hirayama F, Uekama K, Hirano M, Okamoto (1999) Characterization of itraconazole/2-hydroxypropyl-β-cyclodextrin inclusion complex in aqueous propylene glycol solution. Int J Pharm 179: 237-245.
21. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME (2002) Characterization of the interaction of 2-hydroxypropyl-β- cyclodextrin with itraconazole at pH 2, 4 and 7. J Pharm Sci 91: 1414-1422.
22. Pitha J, Hoshino T (1991) Effects of ethanol on formation of inclusion complexes of hydroxypropylcyclodextrins with testosterone or with methyl orange. Int J Pharm 80: 243-251.
23. Rajewski RA, Stella VJ (1996) Pharmaceutical applications of cyclodextrins. 2. In vivo delivery. J Pharm Sci 85: 1142-1169.
24. Stevens DA (1999) Itraconazole in cyclodextrin solution. Pharmacotherapy 19: 603-611.
25. Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21: 201-230.
26. Szejtli J (1988) Cyclodextrin technology, Topics in inclusion science, Kluwer Academic Publishers, Dordrecht, The Netherlands.
27. Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, Woestenborghs R, Groen K, Colardyn F (1997) Concentrations in plasma and safety, of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 41: 2714-2718.
28. Van Peer A, Woestenborghs W, Heykants J, Gasparini R, Gauwenbergh G (1989) The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 36: 423-426.
29. Willems L, van der Geest R, de Beule K (2001) Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 26: 159-169.
30. Zhou H, Goldman M, Wu J, Woestenborghs R, Hassell A, Lee P (1998) A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 38: 593-602.